Acadia Pharmaceuticals | ACAD - Current Assets


Acadia Pharmaceuticals reported $1.1B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 54.84B 794M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
J&J USD 59.77B 601M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Pfizer USD 42.82B 76M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026